Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinotecan
The introduction of nal-IRI plus 5-FU/LV was associated with improved second-line treatment outcomes, providing a new combination regimen with acceptable toxicity in metastatic or recurrent pancreatic cancer.
Authors
- Takeshi Okamoto (ORCID: https://orcid.org/0000-0001-9719-0282)
- Naoki Sasahira (ORCID: https://orcid.org/0000-0002-0672-7214)
- Keito Suzuki (ORCID: https://orcid.org/0000-0001-6234-6064)
- Tatsuki Hirai (ORCID: https://orcid.org/0009-0007-9222-0594)
- Yuri Maegawa
- Masato Ozaka (ORCID: https://orcid.org/0000-0002-5666-1970)
- Takafumi Mie (ORCID: https://orcid.org/0000-0002-7561-5558)
- Takaaki Furukawa (ORCID: https://orcid.org/0000-0002-9746-6776)
- Takashi Sasaki (ORCID: https://orcid.org/0000-0001-7109-9835)
- Tsuyoshi Takeda (ORCID: https://orcid.org/0000-0002-0786-8166)
- Yukari Suzuki (ORCID: https://orcid.org/0000-0002-9625-4616)
- Jun Hamada
- Yoichiro Sato
Institutions
- Cancer Institute (WIA) (IN)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/jjco/hyaf194
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00